We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current NVZMF market cap is 24.09B. The company's latest EPS is DKK 7.2946 and P/E is 7.68.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Revenue | 14.37B | 14.01B | 14.95B | 17.55B | 17.9B |
| Operating Income | 4.03B | 3.65B | 3.94B | 4.55B | 3.96B |
| Net Income | 3.15B | 2.83B | 3.15B | 3.68B | 3.02B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Assets | 20.44B | 20.51B | 24.77B | 27.98B | 28.39B |
| Total Liabilities | 8.96B | 9.27B | 12.56B | 13.76B | 14.04B |
| Total Equity | 11.48B | 11.24B | 12.21B | 14.23B | 14.35B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Operating | 3.2B | 4.36B | 4.06B | 4.01B | 4.15B |
| Investing | -561M | -1.52B | -2.75B | -2.67B | -2.13B |
| Financing | -2.64B | -2.31B | -1.59B | -1.25B | -1.89B |
| Market Cap | 24.09B |
| Price to Earnings Ratio | 7.68 |
| Price to Sales Ratio | 1.3 |
| Price to Cash Ratio | 20.8 |
| Price to Book Ratio | 1.62 |
| Dividend Yield | - |
| Shares Outstanding | 414.56M |
| Average Volume (1 week) | 311 |
| Average Volume (1 Month) | 694 |
| 52 Week Change | 14.68% |
| 52 Week High | 62.80 |
| 52 Week Low | 38.85 |
| Spread (Intraday) | 4.46 (7.17%) |
| Company Name | Novonesis AS (PK) |
| Address |
krogshoejvej 36 bagsvaerd 2880 |
| Website | https://www.novozymes.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
